SCHEDULE 13G/A: L.I.A. Pure Capital Discloses 9.97% Stake in Clearmind Medicine
Beneficial Ownership Report
L.I.A. Pure Capital Ltd. reported a 9.97% beneficial ownership stake in Clearmind Medicine Inc. as of December 3, 2025.
Summary
- L.I.A. Pure Capital Ltd. beneficially owns 5,980,397 common shares of Clearmind Medicine Inc.
- This ownership represents 9.97% of Clearmind Medicine Inc.'s common shares outstanding.
- The percentage is calculated based on 59,991,852 common shares, no par value per share, issued and outstanding, as reported by Clearmind Medicine Inc. in a prospectus supplement filed on December 3, 2025.
- L.I.A. Pure Capital Ltd. holds sole voting power and sole dispositive power over all 5,980,397 shares.
Sentiment
Score: 5
Explanation: Neutral, as this is a factual regulatory disclosure of beneficial ownership, not a performance report or strategic announcement.
Future Outlook
The reporting person certified that the securities were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer, nor in connection with any transaction having that purpose or effect, other than activities solely in connection with a nomination under §§ 240.14a-11.
Management Comments
- Kfir Silberman, Chief Executive Officer of L.I.A. Pure Capital Ltd., certified that, to the best of his knowledge and belief, the securities were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer, and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under §§ 240.14a-11.
Industry Context
This filing is a regulatory disclosure of a significant ownership stake by an institutional investor in a publicly traded company. It does not provide broader industry trends or competitive analysis.
Stakeholder Impact
- Shareholders: The disclosure of a significant institutional ownership stake (9.97%) by L.I.A. Pure Capital Ltd. provides transparency regarding the company's ownership structure. This can be viewed by some as a vote of confidence from an institutional investor.
Key Dates
| Date | Description |
|---|---|
| 12/03/2025 | Date of the event which required the filing of this statement, and the date Clearmind Medicine Inc. reported 59,991,852 common shares outstanding. |
| 12/10/2025 | Date of filing of this Schedule 13G Amendment No. 1. |
Keywords
Clearmind Medicine Inc., L.I.A. Pure Capital Ltd., Schedule 13G, Beneficial Ownership, Common Shares, Institutional Investor, Equity Stake
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.